Clinical trials
Completed Phase 2/3 Leukemia, Myeloid, Acute trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
21 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2013 | 1 |
| 2015 | 3 |
| 2016 | 2 |
| 2018 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Nanfang Hospital, Southern Medical University | 3 |
| Ann & Robert H Lurie Children's Hospital of Chicago | 1 |
| AstraZeneca | 1 |
| Basilea Pharmaceutica | 1 |
| Byung-Sik Cho | 1 |
| Chimeric Therapies | 1 |
| Gamida Cell -Teva Joint Venture Ltd. | 1 |
| Gruppo Italiano Trapianto di Midollo Osseo | 1 |
| Janssen Research & Development, LLC | 1 |
| M.D. Anderson Cancer Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 21 |
| Myelodysplastic Syndromes | 7 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 |
| Anemia, Refractory, with Excess of Blasts | 5 |
| Leukemia | 5 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 |
| Leukemia, Myeloid, Accelerated Phase | 3 |
| Leukemia, Myeloid, Chronic-Phase | 3 |
| Anemia, Refractory | 2 |
| Congenital Abnormalities | 2 |
Trials
Showing 1 to 21 of 21. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.